Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Fixed-Dose Combo Therapy for Prevention of ASCVD

Cochrane Database; ePub 2017 Mar 6; Bahiru, et al

The effects of fixed-dose combination therapy on all-cause mortality and fatal and nonfatal heart attacks and strokes are uncertain; however, modest increases in adverse events were observed when compared to placebo. This according to an updated review that included 4 studies (n=2,102 participants, mean age range 62-63 years) with individuals with a prior heart attack or stroke or with a high predicted risk for having an initial heart attack and 5 studies that had long-term follow-up (≥12 months). Most participants were middle-aged men with moderate elevations in blood pressure (BP) or cholesterol. The fixed-dose combinations ranged from 2 to 5 drugs; all studies included at least 1 BP-lowering and 1 cholesterol-lowering drug. Researchers found:

  • The effects of fixed-dose combination drug therapy on all-cause mortality and fatal and nonfatal heart attacks and strokes are uncertain.
  • Fixed-dose combination drug therapy leads to more adverse events than control (32% vs 27%), including placebo.
  • Fixed-dose combination therapy may modestly lower BP and cholesterol and appears to improve adherence to medications to prevent ASCVD.

Citation:

Bahiru E, de Cates AN, Farr MRB, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No.:CD009868. doi:10.1002/14651858.CD009868.pub3.

This Week's Must Reads

Evolocumab Lowers LDL-C in Patient Subgroups, Clin Cardiol; 2018 Oct 21; Stroes, Robinson, et al

Is Further Lowering of LDL-C in Patients Safe?, JAMA Cardiol; 2018 Sep; Sabatine, Wiviott, et al

Effects of Primary Prevention on CVD Event Risk, J Manag Care Spec Pharm; 2018 Nov; Han, et al

FH Patients with Diabetes at Elevated Risk for CVD, J Clin Lipidol; ePub 2018 Sep 17; Paquette, et al

Long-Term Benefit to Statin Eligibility, JAMA Cardiol; ePub 2018 Oct 24; Thanassoulis, et al

Must Reads in CAD & Atherosclerosis

CAD Severity as a Function of Patient Sex, Am Heart J; ePub 2018 Oct 2; Pagidipati, et al

Does Aspirin Prevent CV Events in Older Adults?, N Engl J Med; ePub 2018 Sep 16; McNeil, et al

FFR and Quality of Life After PCI, Circulation; ePub 2018 Sep 18; Nishi, et al

Does Dietary Diversity Promote a Healthy Weight?, Circulation; ePub 2018 Aug 9; de Oliveira, et al

Omega-3 Fatty Acids for Prevention of CVD, Cochrane Library; ePub 2018 Jul 18; Abdelhamid, et al